Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.
about
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerSubcutaneous unfractionated heparin for the initial treatment of venous thromboembolismAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerFixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolismMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewDosing and monitoring of low-molecular-weight heparins in special populations.Heparin in interventional radiology: a therapy in evolutionParenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesThe potential benefits of low-molecular-weight heparins in cancer patientsIn situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.Problems in laboratory monitoring of heparin dosage.Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.Anticoagulation in chronic kidney disease patients-the practical aspects.Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.Management of venous thromboembolism in patients with cancer: role of dalteparin.Are all low molecular weight heparins equivalent in the management of venous thromboembolism?Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).Audit of anticoagulation after embolectomy for acute ischaemia.Update on pharmacologic therapy for pulmonary embolism.Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.Low-molecular-weight heparins for the treatment of venous thromboembolism.Preparation and evaluation of a novel oral delivery system for low molecular weight heparin.Low-molecular-weight heparins for acute coronary syndromes.Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.Enoxaparin should be used cautiously in patients with end-stage renal disease.Effects of some pharmacological agents on the survival of unipedicled venous flaps: an experimental study.Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics.Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism.Valvular heart disease and pregnancy part II: management of prosthetic valves.The Treatment of Proximal Vein Thrombosis with Subcutaneous Low-Mole Molecular-Weight Heparin Compared with Continuous Intravenous Heparin
P2860
Q24193871-69A9797E-33E7-4E5C-9D7B-1304EAD3728EQ24234155-FBC57536-B892-4716-AFFA-BB1E3335EF7BQ24235193-69983BD0-2813-4B27-BE23-83BD1BD13D1AQ24235236-F382F0E7-EE97-443A-BA33-6D8C21559ECFQ24236443-C5BFD9A3-A08F-48ED-8ADD-91899734F489Q24240038-29A959EC-F3C5-42CD-966C-AAB174DD3318Q24242243-524AAFA1-BDEA-4DA8-B845-260C8A8D0461Q24245782-2942348A-0673-456E-83CA-150C663F253AQ26992262-56071553-A655-4862-BA7E-78794DA6801AQ32049893-EF5563DD-BBA0-42CC-9077-049387DE3DACQ33394179-978836EB-224B-46DE-9074-21FBD9E8CA53Q33399576-70115C59-FFDB-4720-BA42-FF7AF677ACC3Q33698360-8DBDAFB6-6A6E-48DA-8711-8452DADC89A1Q33894433-714D3BB1-6DFC-4C6D-AB54-7D2D3CB9272FQ34106860-D90B9D76-8883-4EA8-8FFE-A71A98CC9922Q34278853-640A5689-AE31-4C21-B798-AF6F83CFAE6CQ34550908-9604D179-1AE6-4520-A9CB-780E8F4A00EFQ35232128-FC454FCC-B193-4FFA-B3A8-E6117FF9F0FBQ36164019-AADB99CE-ACC5-43F7-8C41-F1F8269F6D79Q36812767-2AFAAAAA-59B7-497F-B9DF-C2A29AD488B2Q37278718-02C7F059-4C60-487B-9E53-6F95E2D61C38Q37453595-B8D0CE85-020A-41F9-BC35-42ACD02FE9E3Q37532738-1D040F58-87BC-40C6-B31F-1F9B35C97870Q38157555-DB2A4F53-E43A-4006-A00B-32393C7750F3Q38962411-161E69BF-D34C-4304-9372-4FF5793AB124Q40785363-67634FE9-ACFE-4174-A5CB-C29FBD760615Q41550747-8427F7DD-C8FC-4FA6-8B88-A3F099E30E4EQ41707230-82B60307-D09D-4052-A439-99E63A4C0C3BQ43000667-2FBD5BA0-77DA-421B-AB38-6601E0FAF830Q43805854-0A52EA48-D585-44B7-8974-623D6E8CA953Q43834007-B9FC9CB2-4091-4D41-AA94-7F0359CD9A06Q47175046-7468B92E-E5C6-43B4-8F5A-CBB1402E284CQ47285242-839A88CD-3E7B-4259-AAA6-89744892FE0EQ47546619-A4409821-9E64-4CC1-A94E-528A35B6E430Q59139683-8C000A26-CD7C-4CB1-9234-B45800D261AC
P2860
Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@en
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@nl
type
label
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@en
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@nl
prefLabel
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@en
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@nl
P2093
P356
P1476
Dose adjusted heparin treatmen ...... low molecular weight heparin.
@en
P2093
G F Handeland
K E Arnesen
U Abildgaard
P2860
P2888
P304
P356
10.1007/BF00280041
P577
1990-01-01T00:00:00Z